NCT07609160Not yet recruiting
Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals
Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals: a Randomized Controlled Trial Protocol
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
This randomized controlled trial aims to investigate the effects of a 24-week home-based progressive resistance exercise program combined with tirzepatide treatment on skeletal muscle mass, muscle quality, and functional capacity in overweight and obese individuals. A total of 108 participants initiating tirzepatide therapy will be randomized to either exercise plus pharmacotherapy or pharmacotherapy alone. The primary outcome is change in thigh muscle thickness and echo intensity assessed by ultrasonography.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- First submitted
- 28 Apr 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 30 Nov 2027
- Lead sponsor
- Acibadem University
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07609160
What you commit to
- Study type: Interventional
- Planned participants: 108
- From 1 Nov 2026 to the primary completion date, 30 Nov 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- use of weight-loss medications within the past 12 months
Other illness
- diagnosis of type 1 or type 2 diabetes mellitus
- presence of cerebrovascular, hematological, pulmonary, rheumatological, or neurological disorders
- history of upper or lower extremity surgery or injury within the past 6 months
Other
- current participation in a structured diet or exercise program
- any contraindication to resistance exercise as determined by the treating physician.
Who the study is looking for
- initiation of tirzepatide-based pharmacological treatment as prescribed by an endocrinology and metabolism specialist,
- body mass index (BMI) ≥27 kg/m² and the presence of a comorbidity condition or BMI≥30 kg/m²
- age between 18 and 65 years
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.